English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17419/19718 (88%)
Visitors : 6157132      Online Users : 805
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/32256


    標題: Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma
    作者: Wu, Wei-De
    Chen, Pin-Shern
    Omar, Hany A.
    Arafa, El-Shaimaa A.
    Pan, Hung-Wei
    Jeng, Jingyueh
    Hung, Jui-Hsiang
    貢獻者: Chia Nan Univ Pharm & Sci, Dept Biotechnol
    Univ Sharjah, Sharjah Inst Med Res
    Univ Sharjah, Coll Pharm
    Ajman Univ, Dept Clin Sci, Coll Pharm
    Beni Suef Univ, Dept Pharmacol, Fac Pharm
    Kaohsiung Vet Gen Hosp, Dept Med Educ & Res
    Chia Nan Univ Pharm & Sci, Drug Discovery & Dev Ctr
    關鍵字: Human Hepatoma-Cells
    Kappa-B Pathway
    Tumor-Growth
    Signaling Pathway
    Cancer Cells
    Raf/Mek/Erk Pathway
    Inhibits Migration
    Over-Expression
    Fruiting Bodies
    Cycle Arrest
    日期: 2018-08-27
    上傳時間: 2019-11-15 15:47:04 (UTC+8)
    出版者: NATURE PUBLISHING GROUP
    摘要: Hepatocellular carcinoma (HCC) has been recognized worldwide as one of the major causes of cancer death. The medicinal fungus Antrodia cinnamomea (A. cinnamomea) has been served as a functional food for liver protection. The aim of the present study was to investigate the potential activity of A. cinnamomea extracts as a safe booster for the anticancer activity of sorafenib, a multi-kinase inhibitor approved for the treatment of HCC. The biologically active triterpenoids in the ethanolic extracts of A. cinnamomea (EAC) were initially identified by HPLC/LC/MS then the different extracts and sorafenib were assessed in vitro and in vivo. EAC could effectively sensitize HCC cells to low doses of sorafenib, which was perceived via the ability of the combination to repress cell viability and to induce cell cycle arrest and apoptosis in HCC cells. The ability of EAC to enhance sorafenib activity was mediated through targeting mitogen-activated protein (MAP) kinases, modulating cyclin proteins expression and inhibiting cancer cell invasion. Moreover, the proposed combination significantly suppressed ectopic tumor growth in mice with high safety margins compared to single-agent treatment. Thus, this study highlights the advantage of combining EAC with sorafenib as a potential adjuvant therapeutic strategy against HCC.
    link: http://dx.doi.org/10.1038/s41598-018-31209-8
    關聯: Scientific Reports, v.8, 12914
    Appears in Collections:[生物科技系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.1007-s13197-018-3148-4.pdf4992KbAdobe PDF73View/Open
    index.html0KbHTML151View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback